1-20 of 78 results for subject:Pain
Librarians' tools
- Search time
- 0.307 seconds
- Solr query time
- 0.004 seconds
- Search query
- subject:Pain
- We searched for
- subject_t:Pain OR subject_ses:92323
Type
House
Session
More
Year
Department
Member
More
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
I would be very happy to meet the hon. Lady and her colleague. We are determined to continue to improve PIP—31% of claimants now access the highest rate of support, compared to just 15% under the legacy benefits—but I would welcome any additional information.
I would be very happy to meet the hon. Lady and her colleague. We are determined to continue to improve PIP—31% of claimants now access the highest rate of support, compared to just 15% under the legacy benefits—but I would welcome any additional information.
Last month, I met my constituent Dr Karen Gilmore, a specialist in pain management, and several of her colleagues and members of the independent assessment service. We discussed how the personal independence payment assessments in particular do not meet the needs of people living with chronic and severe pain. Will the Minister meet Dr Gilmore and me to discuss how we can improve these assessments?
Last month, I met my constituent Dr Karen Gilmore, a specialist in pain management, and several of her colleagues and members of the independent assessment service. We discussed how the personal independence payment assessments in particular do not meet the needs of people living with chronic and severe pain. Will the Minister meet Dr Gilmore and me to discuss how we can improve these assessments?
Last month, I met my constituent Dr Karen Gilmore, a specialist in pain management, and several of her colleagues and members of the independent assessment service. We discussed how the personal independence payment assessments in particular do not meet the needs of people living with chronic and severe pain. Will the Minister meet Dr Gilmore and me to discuss how we can improve these assessments?
I would be very happy to meet the hon. Lady and her colleague. We are determined to continue to improve PIP—31% of claimants now access the highest rate of support, compared to just 15% under the legacy benefits—but I would welcome any additional information.
To ask the Secretary of State for Justice, on what date he (a) received and (b) plans to publish Charlie Taylor’s report on the use of pain-inducing restraint on children.
To ask the Secretary of State for Justice, on what date he (a) received and (b) plans to publish Charlie Taylor’s report on the use of pain-inducing restraint on children.
Charlie Taylor undertook to submit his findings and recommendations on the use of pain-inducing techniques in the restraint of children in the secure estate by the Summer, and I expect to receive his report shortly.
The Department will of course need to consider Charlie Taylor’s findings and recommendations carefully and we will publish both the report and the Government response as soon as we have done so.
To ask Her Majesty's Government what plans they have, if any, to extend the availability of medicinal cannabis to people with diseases that cause chronic pain.
To ask Her Majesty's Government what plans they have, if any, to extend the availability of medicinal cannabis to people with diseases that cause chronic pain.
The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.
The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.
An initial impact assessment Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.
To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.
To ask Her Majesty's Government what assessment they have made of (1) the advantages, and (2) the disadvantages, of allowing medical professionals to prescribe medicinal cannabis to people suffering from chronic pain.
To ask Her Majesty's Government what assessment they have made of (1) the advantages, and (2) the disadvantages, of allowing medical professionals to prescribe medicinal cannabis to people suffering from chronic pain.
The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.
The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.
An initial impact assessment Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.
To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.
To ask Her Majesty's Government what studies (1) have been carried out, and (2) are proposed, to investigate the pain relief impacts of medicinal cannabis on people who have multiple sclerosis.
To ask Her Majesty's Government what studies (1) have been carried out, and (2) are proposed, to investigate the pain relief impacts of medicinal cannabis on people who have multiple sclerosis.
The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.
The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.
An initial impact assessment Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.
To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.
To ask the Secretary of State for Health and Social Care, when electrical stimulation for arthritis pain will be available on the NHS.
To ask the Secretary of State for Health and Social Care, when electrical stimulation for arthritis pain will be available on the NHS.
We are aware of recent research looking at electrical stimulation of the vagus nerve to treat patients with rheumatoid arthritis. This was a small pilot study of 14 people, and therefore research remains at an early stage. In order to be suitable for routine National Health Service use, larger scale clinical trials demonstrating the safety and efficacy of this treatment approach would need to be undertaken, and assessments of its cost effectiveness would also need to be considered.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of prescribing mindfulness-based pain management in treating chronic pain.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of prescribing mindfulness-based pain management in treating chronic pain.
No specific assessment has been made. However, self-management approaches, such as mindfulness, may be appropriate for helping people manage the day to day symptoms of living with a long-term condition, such as chronic pain.
The National Institute for Health and Care Excellence is in the process of developing the ‘Chronic Pain: assessment and management’ guideline, which is expected for publication on 19 August 2020. The guideline is looking at range of approaches relevant to the management of chronic pain, including pain self-management programmes and peer-led programmes. The guideline scope document can be found at the following link:
www.nice.org.uk/guidance/gid-ng10069/documents/final-scope
My Lords, I declare my interests as noted in the register, particularly my interests in accessible transport, housing and charities.
The lives of disabled people are often challenging. We rightly work hard to try to meet those challenges, and many disabled people say that we do not work
hard enough. But the...
My Lords, I declare my interests as noted in the register, particularly my interests in accessible transport, housing and charities.
The lives of disabled people are often challenging. We rightly work hard to try to meet those challenges, and many disabled people say that we do not work
hard enough. But the...
My Lords, it is a pleasure to congratulate the noble Lord, Lord Borwick, on securing this debate and also on an excellent speech, which I am glad to follow. When we speak about minorities, we all too often lose sight of the fact that disabled people are the largest minority...
My Lords, it is a pleasure to congratulate the noble Lord, Lord Borwick, on securing this debate and also on an excellent speech, which I am glad to follow. When we speak about minorities, we all too often lose sight of the fact that disabled people are the largest minority...
My Lords, when it comes to disability, the first thing that strikes me is how incredibly wide the field is. There is a grave danger that when we talk about disability we start to talk about a bit of it. I am afraid that virtually all the lobby groups—although it...
My Lords, when it comes to disability, the first thing that strikes me is how incredibly wide the field is. There is a grave danger that when we talk about disability we start to talk about a bit of it. I am afraid that virtually all the lobby groups—although it...
My Lords, I congratulate my noble friend Lord Borwick on bringing this very important debate to the Chamber today. I am very pleased to follow the noble Lord, Lord Addington. The point that he made about the breadth of disability is very important because, for many people born with a...
My Lords, I congratulate my noble friend Lord Borwick on bringing this very important debate to the Chamber today. I am very pleased to follow the noble Lord, Lord Addington. The point that he made about the breadth of disability is very important because, for many people born with a...
My Lords, I too congratulate the noble Lord, Lord Borwick, on knitting together two very different issues: the here-and-now problems that disabled people have in their everyday lives and the potential for improved treatment and outcomes in the next 50 years.
If we look back 50 years, there are many life-enhancing...
My Lords, I too congratulate the noble Lord, Lord Borwick, on knitting together two very different issues: the here-and-now problems that disabled people have in their everyday lives and the potential for improved treatment and outcomes in the next 50 years.
If we look back 50 years, there are many life-enhancing...
I thank the noble Lord, Lord Borwick, for tabling this debate today. He has been a great friend of disabled people, championing developments in housing, transport and deaf children’s inclusion in education. I am also glad that he mentioned Bert Massie, an exceptional disabled person whom I had the pleasure...
I thank the noble Lord, Lord Borwick, for tabling this debate today. He has been a great friend of disabled people, championing developments in housing, transport and deaf children’s inclusion in education. I am also glad that he mentioned Bert Massie, an exceptional disabled person whom I had the pleasure...
My Lords, it is a pleasure to take part in today’s debate and I congratulate my noble friend Lord Borwick on having such a visionary title for it. Few people have done as much as he has on access to transport, not least when it comes to London’s licensed taxis....
My Lords, it is a pleasure to take part in today’s debate and I congratulate my noble friend Lord Borwick on having such a visionary title for it. Few people have done as much as he has on access to transport, not least when it comes to London’s licensed taxis....
My Lords, I, too, thank the noble Lord, Lord Borwick, for tabling this debate—I have to say, he made me smile. Unfortunately, some of the discrimination that I still experience these days is people wafting a hand in my direction and telling me that people like me cannot do lots...
My Lords, I, too, thank the noble Lord, Lord Borwick, for tabling this debate—I have to say, he made me smile. Unfortunately, some of the discrimination that I still experience these days is people wafting a hand in my direction and telling me that people like me cannot do lots...
My Lords, I am indebted to my noble friend Lord Borwick for tabling this far-seeing debate. I remind your Lordships of my registered interest as the chairman of the stroke charity ARNI, Action for Rehabilitation from Neurological Injury.
Stroke is the leading cause of disability in the United Kingdom and there...
My Lords, I am indebted to my noble friend Lord Borwick for tabling this far-seeing debate. I remind your Lordships of my registered interest as the chairman of the stroke charity ARNI, Action for Rehabilitation from Neurological Injury.
Stroke is the leading cause of disability in the United Kingdom and there...
My Lords, I am delighted to follow the noble Lord, Lord Lingfield, who demonstrates how many types of disability we have to consider. I thank the noble Lord, Lord Borwick, for setting us the very good challenge of imagining where we would like to be in the field of disabilities...
My Lords, I am delighted to follow the noble Lord, Lord Lingfield, who demonstrates how many types of disability we have to consider. I thank the noble Lord, Lord Borwick, for setting us the very good challenge of imagining where we would like to be in the field of disabilities...
My Lords, it is a pleasure to follow the noble Lord, Lord Luce; pain is such an important issue. I thank the noble Lord, Lord Borwick, for securing this debate on issues facing people with disabilities. Disability can be complicated and varied, as has been illustrated by this debate today....
My Lords, it is a pleasure to follow the noble Lord, Lord Luce; pain is such an important issue. I thank the noble Lord, Lord Borwick, for securing this debate on issues facing people with disabilities. Disability can be complicated and varied, as has been illustrated by this debate today....
My Lords, I too applaud the noble Lord, Lord Borwick, for initiating this helpful debate. If we want to improve outcomes in the disability field in the next 50 years, surely the best way of doing so, where we possibly can, is to prevent disability occurring in the first place....
My Lords, I too applaud the noble Lord, Lord Borwick, for initiating this helpful debate. If we want to improve outcomes in the disability field in the next 50 years, surely the best way of doing so, where we possibly can, is to prevent disability occurring in the first place....